Synlogic Inc (NASDAQ:SYBX) – Stock analysts at Leerink Swann issued their Q1 2018 EPS estimates for shares of Synlogic in a note issued to investors on Wednesday. Leerink Swann analyst J. Schwartz expects that the biotechnology company will post earnings of ($0.63) per share for the quarter. Leerink Swann also issued estimates for Synlogic’s Q2 2018 earnings at ($0.60) EPS, Q3 2018 earnings at ($0.58) EPS and Q4 2018 earnings at ($0.56) EPS.
Several other research firms have also weighed in on SYBX. Zacks Investment Research upgraded shares of Synlogic from a “sell” rating to a “hold” rating in a research note on Saturday, January 20th. Wedbush began coverage on shares of Synlogic in a research note on Monday, November 27th. They issued an “outperform” rating and a $20.00 price objective on the stock. ValuEngine lowered shares of Synlogic from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. HC Wainwright began coverage on shares of Synlogic in a research note on Monday, March 19th. They issued a “buy” rating and a $20.00 price objective on the stock. Finally, Piper Jaffray Companies began coverage on shares of Synlogic in a research note on Monday, January 29th. They issued an “overweight” rating and a $16.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. Synlogic presently has a consensus rating of “Hold” and a consensus target price of $19.00.
Several institutional investors and hedge funds have recently made changes to their positions in SYBX. Spark Investment Management LLC acquired a new position in shares of Synlogic during the 4th quarter worth $105,000. Deutsche Bank AG increased its stake in shares of Synlogic by 204.0% during the 4th quarter. Deutsche Bank AG now owns 19,672 shares of the biotechnology company’s stock worth $190,000 after purchasing an additional 13,200 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of Synlogic during the 4th quarter worth $191,000. Finally, Artal Group S.A. acquired a new position in shares of Synlogic during the 4th quarter worth $5,335,000. Institutional investors own 50.71% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Leerink Swann Comments on Synlogic Inc’s Q1 2018 Earnings (SYBX)” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/3297734/leerink-swann-comments-on-synlogic-incs-q1-2018-earnings-sybx.html.
Synlogic Company Profile
Synlogic, Inc, formerly Mirna Therapeutics, Inc, is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.
